Jacky Vonderscher

Company: ENYO Pharma

Job title: Co-Founder & Chief Executive Officer

Seminars:

Vonafexor is a Fibrolytic & Anti-Inflammatory Product Destinated to Common & Rare Renal Diseases Including CKD & Alport Syndrome 11:30 am

Vonafexor is a once-daily oral candidate with fibrolytic and anti-inflammatory features Vonafexor is entering a Phase 2 study in Alport Syndrome in 1H 2023 Vonafexor improves renal function in clinics and kidney morphology in Alport syndrome and CKD preclinical modelsRead more

day: Track 1 - Day 1 AM